Fig. 1 Platinum complexes which entered clinical trials While most of the platinum drugs have to be administered intravenously, Satraplatin (8) was the first orally applicable platinum agent under clinical…
Fig. 1 Lung cancer incidence and mortality rates by sex and age, United States, 2006–2010. Rates are per 100,000 and age-adjusted to the 2000 U.S. standard population During 2006–2010, the…
Fig. 1 KRAS signaling. KRAS acts to integrate external signals from extracellular ligands that bind transmembrane growth factor receptors. The KRAS protein is localized to the cell membrane via farnesylation…
Drug name Generic name Target Status Reversible ZD1839 Gefitinib EGFR Approved OSI776 Erlotinib EGFR Approved BPI-2009H Icotinib EGFR Approved TAK-165 Mubritinib EGFR/ERBB2 Phase I XL647 NA EGFR/ERBB2/FLT-4 Phase II…
Risk factor Risk ratio Comments References Second hand smoke 1.34 Prospective nested case control in Europe [27] 1.23 (spouse) 1.27 (workplace) Pooled analysis from two case controls US & Europe…
Fig. 1 A simplified overview of platinum resistance in lung cancer. Pt platinum, CTR1 copper transporter 1, GSH glutathione, BCRP breast cancer resistance protein Table 1 Tumor factors contributing to…
© Springer International Publishing Switzerland 2016Aamir Ahmad and Shirish Gadgeel (eds.)Lung Cancer and Personalized MedicineAdvances in Experimental Medicine and Biology89310.1007/978-3-319-24223-1_9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer Sai-Hong Ignatius Ou1 and Keisuke Shirai2 (1) Chao Family…
Fig. 1 Ways to leave your EGFR inhibitor: biochemical pathways leading to resistance to small molecule EGFR drugs such as gefitinib and erlotinib. (a) Structures of two approved EGFR TKIs,…
Fig. 1 Vascular endothelial growth factor receptor signal transduction (Reprinted with permission from Roskoski. CROH 2007 62(3):179–213) The role of serum VEGF (VEGF-A) in tumor growth and development has been…
